Dear readers,

In this series, our editors at MashupMD will share highlights in metastatic hormone-sensitive prostate cancer (mHSPC). Today, we want to bring a few recent articles to your attention. First, an sNDA for darolutamide plus ADT was submitted for FDA approval. Our next post ponders whether circulating tumor cell count can be a prognostic biomarker in mHSPC. PFS and OS are weighed in this study to observe patient outcomes.

Additional articles this week focus on everything from how to manage care in private clinics to the best practices in triplet therapy.

Kindly,
Your editors at MashupMD